Last reviewed · How we verify
Casirivimab and Imdevimab Drug Combination
This monoclonal antibody combination blocks the SARS-CoV-2 spike protein, preventing viral attachment and entry into host cells.
This monoclonal antibody combination blocks the SARS-CoV-2 spike protein, preventing viral attachment and entry into host cells. Used for COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease).
At a glance
| Generic name | Casirivimab and Imdevimab Drug Combination |
|---|---|
| Also known as | REGN-COV2 |
| Sponsor | Mansoura University Hospital |
| Drug class | Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies) |
| Target | SARS-CoV-2 spike protein receptor-binding domain |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Casirivimab and imdevimab are two recombinant human monoclonal antibodies that bind to non-overlapping epitopes on the SARS-CoV-2 spike protein receptor-binding domain. By simultaneously targeting the spike protein, they prevent viral attachment to the ACE2 receptor and neutralize the virus, reducing viral load and infection severity. The dual-antibody approach reduces the risk of viral escape mutants.
Approved indications
- COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease)
Common side effects
- Infusion-related reactions
- Hypersensitivity reactions
- Fever
- Chills
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
- COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease (PHASE1, PHASE2)
- A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults (PHASE3)
- COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age (PHASE2)
- COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers (PHASE2)
- COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 (PHASE1)
- COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: